Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Zoledronic Acid

Review the clinical trials studying zoledronic acid on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-6 of 6

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
Status: Active
Location: 7 locations
Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed/Refractory Hematologic Malignancies or High Risk Solid Tumors
Status: Active
Location: 2 locations
Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine with or without Zoledronic Acid in Treating Patients with Locally Advanced Pancreatic Cancer
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Modified Donor Peripheral Blood Stem Cells in Combination with Zoledronic Acid for the Treatment of Pediatric, Adolescent, and Young Adult Patients with Relapsed or Refractory Solid Tumors
Status: Active
Location: University of Florida Health Science Center - Gainesville, Gainesville, Florida
Zanzalintinib with Bone-Strengthening Agents for Treating Clear Cell Renal Cell Cancer Patients with Bone Metastases
Status: Approved
Location: University of California San Francisco, San Francisco, California
Response of Bone Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers with Actionable Driver Mutations
Status: Active
Location: 2 locations